Exicure, Inc. (NASDAQ:XCUR) Short Interest Update

Exicure, Inc. (NASDAQ:XCUR) was the recipient of a large decrease in short interest in April. As of April 15th, there was short interest totalling 27,500 shares, a decrease of 19.8% from the March 31st total of 34,300 shares. Approximately 3.3% of the company’s shares are short sold. Based on an average daily trading volume, of 41,100 shares, the days-to-cover ratio is presently 0.7 days.

Exicure Stock Performance

NASDAQ XCUR opened at $10.73 on Friday. The stock has a market capitalization of $67.79 million, a P/E ratio of -5.18 and a beta of 3.74. Exicure has a 52 week low of $1.44 and a 52 week high of $36.00. The stock has a fifty day moving average of $11.65 and a 200-day moving average of $11.48.

Exicure (NASDAQ:XCUR) last announced its quarterly earnings data on Tuesday, March 18th. The company reported ($3.39) earnings per share for the quarter.

Institutional Trading of Exicure

A hedge fund recently bought a new stake in Exicure stock. Geode Capital Management LLC acquired a new stake in Exicure, Inc. (NASDAQ:XCUR) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 12,645 shares of the company’s stock, valued at approximately $173,000. Geode Capital Management LLC owned about 0.48% of Exicure at the end of the most recent quarter. 42.82% of the stock is owned by institutional investors and hedge funds.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.